A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma
Annals of Surgery, ISSN: 0003-4932, Vol: 249, Issue: 2, Page: 195-202
2009
- 179Citations
- 76Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations179
- Citation Indexes177
- 177
- CrossRef115
- Clinical Citations1
- PubMed Guidelines1
- Policy Citations1
- Policy Citation1
- Captures76
- Readers76
- 76
- Mentions1
- News Mentions1
- News1
Most Recent News
The Efficacy of Hepatectomy or TILA-TACE in Patients With Resectable Hepatocellular Carcinoma
STUDY INFORMATION OFFICIAL TITLE: A Randomized Controlled Trial of the Efficacy of Hepatectomy or TILA-TACE in Patients With Resectable Hepatocellular Carcinoma CURRENT STATUS: Not yet
Article Description
OBJECTIVE:: To evaluate the effect of preoperative transarterial chemoembolization (TACE) for resectable large hepatocellular carcinoma (HCC). SUMMARY BACKGROUND DATA:: Resection of HCC is potentially curative, but local recurrence is very common. There is currently no effective neoadjuvant or adjuvant therapy. METHODS:: From July 2001 to December 2003, 108 patients (hepatitis B carrier ≤ 98.1%) with resectable HCC (ĝ‰¥5 cm) was randomly assigned to preoperative TACE treatment (n ≤ 52) or no preoperative treatment (control group) (n ≤ 56). RESULTS:: Five patients (9.6%) in the preoperative TACE group did not receive surgical therapy because of extrahepatic metastasis or liver failure. The preoperative TACE group had a lower resection rate (n ≤ 47, 90.4% vs. n ≤ 56, 100%; P≤ 0.017), and longer operative time (mean, 176.5 minutes vs. 149.3 minutes; P≤ 0.042). No significant difference was found between the 2 groups in operative blood loss, surgical morbidity, and hospital mortality.At a median follow-up of 57 months, 41 (78.8%) of 52 patients in the preoperative TACE group and 51 (91.1%) of 56 patients in the control group had recurrent disease (P≤ 0.087). The 1-, 3-, and 5-year disease-free survival rates were 48.9%, 25.5%, and 12.8%, respectively, for the preoperative TACE group and 39.2%, 21.4%, and 8.9%, respectively, for the control group (P≤ 0.372). The 1-, 3-, and 5-year overall survival rates were 73.1%, 40.4%, and 30.7%, respectively, for the preoperative TACE group and 69.6%, 32.1%, and 21.1%, respectively, for the control group (P≤ 0.679). CONCLUSIONS:: Preoperative TACE did not improve surgical outcome. It resulted in drop-out from definitive surgery because of progression of disease and liver failure. © 2009 by Lippincott Williams & Wilkins.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=61549106905&origin=inward; http://dx.doi.org/10.1097/sla.0b013e3181961c16; http://www.ncbi.nlm.nih.gov/pubmed/19212170; https://journals.lww.com/00000658-200902000-00004; http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00000658-200902000-00004; https://dx.doi.org/10.1097/sla.0b013e3181961c16; https://journals.lww.com/annalsofsurgery/Abstract/2009/02000/A_Prospective,_Randomized,_Controlled_Trial_of.4.aspx
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know